Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma) confirmed a transition to electronic delivery for all future corporate communications in line with Rule 2.07A of the Hong Kong Stock Exchange Listing Rules and the company’s Articles of Association. The change is effective immediately and applies to both informational and actionable documents.

Actionable corporate communications—materials requiring shareholder instructions—will be emailed individually. If a valid email address is not available or proves non-functional, Haixi Pharma will mail a printed copy together with a form requesting an updated email address.

General corporate communications, including annual, interim and any quarterly reports, meeting notices, circulars and proxy forms, will be posted on the company website (hxpharma.com) and the HKEX website (hkexnews.hk). No separate notice of publication will be sent; shareholders are expected to monitor the two websites for new releases.

To facilitate electronic communication, shareholders are asked to submit a functional email address by completing an online form accessible via the QR code provided in the notice, valid until 30 May 2026. Alternatively, email addresses can be supplied at any time to the Hong Kong share registrar, Tricor Investor Services Limited, by post or email (2637-ecom@vistra.com).

Printed copies of any corporate or actionable communication will remain available free of charge upon written request to the share registrar. Previously stated print preferences will continue unless revoked.

Enquiries regarding the new arrangements can be directed to Tricor’s hotline at +852 2980 1333 during business hours or via the above email address.

The notice was signed by Dr. Kang Xinshan, Chairman and Executive Director, on behalf of Haixi Pharma’s board on 30 April 2026.